FindTrial
Sign In

Understanding the biology of ETP-ALL.

Early T-cell precursor acute lymphoblastic leukaemia: Unravelling mechanisms of resistance and development of novel therapeutic strategies. - ETP ALL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/03/041157
Enrollment
50
Registered
2022-03-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C948- Other specified leukemias

Interventions

Intervention1: None: None Control Intervention1: None: None

Sponsors

Lady Tata Memorial Trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Study Population Inclusion Criteria are following three Age greater than equal to 15 years Newly diagnosed cases of ETP ALL and T cell ALL Planned for systematic therapy

Exclusion criteria

Exclusion criteria: Exclusion Criteria are following two points Any previous treatment received Unfit for treatment

Design outcomes

Primary

MeasureTime frame
Objective 1: To demonstrate prednisolone resistance and its biological basis in ETP-ALL compared to non ETP subtype of T ALL and to evaluate the impact of prednisolone exposure on the chemosensitivity to other drugs used in ALL induction therapy. Objective 2: To demonstrate the exquisite sensitivity of ETP- ALL to 6-MP as compared to other ALL subtypes and its underlying biological basis. Objective 3: In-vitro and in-vivo validation of sensitivity of ETP-ALL to FDA approved drugs as predicted by in-silico analysis.Timepoint: 4 years—

Secondary

MeasureTime frame
NoneTimepoint: 0—

Countries

India

Contacts

Public ContactDr Manju Sengar

Tata Memorial Hospital

manju.sengar@gmail.com02224177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026